ROR1-Positive Mesenchymal Stem Cells for Enhanced Therapeutic Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesenchymal stem cell therapies have limited therapeutic efficacy due to their inability to effectively differentiate into various tissues and their insufficient impact on diseases such as cancer, inflammatory conditions, and neurodegenerative disorders.
Innovation Solution
Development of ROR1-positive mesenchymal stem cells, which are positive for CD29, CD73, CD90, and CD105, derived from umbilical cord or adipose tissue, demonstrating enhanced therapeutic effects through increased migratory capacity, mitochondrial transfer, and resistance to oxidative stress, and their use in a pharmaceutical composition to treat a range of diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional mesenchymal stem cells are used for therapy, then the treatment can be administered, but the therapeutic efficacy is limited due to insufficient migratory capacity and differentiation ability
Solution Approach 1:
The patent selects and expands mesenchymal stem cells based on specific surface marker parameters (ROR1+, CD105+, CD73+, CD29+, CD90+) to identify and cultivate a population with enhanced therapeutic properties. This parameter-based selection resolves the contradiction by changing the cellular composition parameters to achieve both high migratory capacity and therapeutic efficacy
2Reliability
If conventional mesenchymal stem cells are used, then the treatment procedure is simple, but the impact on diseases such as cancer and neurodegenerative disorders is insufficient
Solution Approach 1:
The patent employs flow cytometry-based sorting using specific surface marker parameters (ROR1, CD105, CD73, CD29, CD90) to isolate and expand a precisely defined stem cell population. This parameter-driven approach enables the selection of cells with superior disease-modifying capabilities while maintaining a systematic preparation process
Solution Approach 2:
The patent uses surface markers (ROR1, CD105, CD73, CD29, CD90) as intermediaries to identify and select stem cells with enhanced therapeutic properties. These markers serve as mediators that enable the isolation of cells with improved efficacy against cancer and neurodegenerative disorders without requiring complex genetic modification
3Reliability
If standard mesenchymal stem cell cultures are used, then the culture process is straightforward, but the cells show insufficient resistance to oxidative stress and limited mitochondrial transfer capability
Solution Approach 1:
The patent selects and expands mesenchymal stem cells based on a specific phenotypic parameter profile (ROR1+, CD105+, CD73+, CD29+, CD90+) that correlates with enhanced oxidative stress resistance and mitochondrial function. This parameter-based selection identifies a cell population with superior stress resistance without requiring complex cultural manipulation
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.